Utama › Kanser Payudara › Nevada
Kajian klinikal Kanser Payudara di Nevada
19 kajian untuk Kanser Payudara sedang mencari peserta di lokasi di Nevada.
Bandar di Nevada
Teks kajian rasmi (Bahasa Inggeris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Cancer Care Specialists, Reno
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- dan 25 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Cancer Care Specialists, Reno
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06369285A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Optum Care Cancer Center ( Site 0050), Las Vegas
- Renown Regional Medical Center ( Site 0041), Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Renown Regional Medical Center, Reno
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT03424005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Reno
Mengambil pesertaFasa 3
Umur 18 hingga 130 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07647328Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Renown Health Medical Oncology, Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Specialist of Reno, Reno
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- dan 25 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07029399A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Comprehensive Cancer Centers of Nevada, Las Vegas
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT06764940Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Comprehensive Cancer Centers of Nevada, Henderson
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT05232916A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT05696626A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Henderson
- Comprehensive Cancer Centers of Nevada, Las Vegas
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07062965De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
- Radiation Oncology Centers of Nevada Central, Las Vegas
- dan 8 lagi
Mengambil pesertaFasa 3
Umur 50 hingga 70 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04852887A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 22 Apr 2026 · NCT05683418Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Renown Regional Medical Center, Reno
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2025 · NCT05216432Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.